Acknowledgments We thank Peter Boknik (Department of Pharmacology and Toxicology, University of M u¨nster, Germany) for kind support with measurements of 14C-labeled TKIs and Rainer Bartsch (Department of Hematology and Oncology, Otto-von-Guericke University Magdeburg, Germany) for technical support. Imatinib and 14C-labeled imatinib were kind gifts from Novartis, Basel, Switzerland. K562-ABCG2 cells were kindly provided by Sheng Zhou (Division of Experimental Hematology, Department of Hematology, St. Jude Childrens Research Hospital, Memphis, USA). References 1. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six- year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054–1061. 2. Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089–5102. 3. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127. 4. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789–796. 5. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, et al. (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91: 163–168. 6. Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, et al. (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111: 4022–4028. 7. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, et al. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496–3499. 8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037. 9. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531–2541. 10. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, et al. (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26: 3204–3212. 11. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, et al. (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95: 232–240. 12. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, et al. (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14: 485–493. 13. Snead JL, O’Hare T, Adrian LT, Eide CA, Lange T, et al. (2009) Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 114: 3459–3463. 14. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, et al. (2009) Short- term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 23: 1205–1206. 15. Markova B, Albers C, Breitenbuecher F, Melo JV, Brummendorf TH, et al. (2010) Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene 29: 739–751. 16. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R (1993) Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 7: 825–831. 17. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, et al. (2005) Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105: 2571–2576. 18. Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, et al. (2003) In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 17: 999–1009. 19. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, et al. (2004) Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells. Cell 118: 217–228. 20. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399–401. 21. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658–6661. Cellular Retention of TKI and Apoptosis Commitment Author Contributions Conceived and designed the experiments: DBL TF. Performed the experiments: MCW MD TS. Analyzed the data: DBL MCW FH TK TF. Wrote the paper: DBL MCW FH TK TF. Performed and analyzed TKI measurements and wrote ‘‘HPLC measurements of TKIs’’ in Materials and Methods: MD. Provided reagents and participated in writing the paper: JVM. Designed and analyzed radioactive drug-uptake and drug-release experiments and participated in writing the paper: MS CMT SK. 22. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108: 1370–1373. 23. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028– 1034. 24. Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, et al. (2010) Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 116: 6144–6145; author reply 6145–6146. 25. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, et al. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 2368–2373. 26. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, et al. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 1267–1275. 27. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, et al. (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28: 265–269. 28. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, et al. (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18: 401–408. 29. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, et al. (2011) Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25: 463–472. 30. Chu S, Li L, Singh H, Bhatia R (2007) BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transforma- tion in chronic myelogenous leukemia. Cancer Res 67: 7045–7053. 31. Pendergast AM, Gishizky ML, Havlik MH, Witte ON (1993) SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 13: 1728–1736. 32. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, et al. (1999) Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189: 1229–1242. 33. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1: 479–492. 34. Pluk H, Dorey K, Superti-Furga G (2002) Autoinhibition of c-Abl. Cell 108: 247–259. 35. Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, et al. (2001) Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene 20: 8075–8084. 36. Brasher BB, Van Etten RA (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275: 35631–35637. 37. Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, et al. (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107: 3279–3287. 38. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, et al. (2006) Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107: 4898–4906. 39. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, et al. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2: 98–110. 40. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, et al. (2012) Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice. Blood. 41. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, et al. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53: 313–323. 42. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739– 3745. 43. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, et al. (2006) OCT- 1-mediated influx is a key determinant of the intracellular uptake of imatinib but PLoS ONE | www.plosone.org 15 July 2012 | Volume 7 | Issue 7 | e40853